Track topics on Twitter Track topics that are important to you
NEW YORK, June 2, 2015 (GLOBE NEWSWIRE) -- The Rosen Law Firm, a global investor rights firm, reminds purchasers of Walgreen, Co. ("Walgreens") (Nasdaq:WBA) securities from March 25, 2014 through August 5, 2014 of the important June 9, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Walgreens investors under the federal securities laws.
To join the Walgreens class action, go to the firm's website at http://www.rosenlegal.com/cases-573.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The lawsuit alleges that Walgreens made false and/or misleading statements, as well as failed to disclose material adverse facts pertaining to the Company's business and prospects, including the purported benefits of Walgreens' strategic partnership with Alliance Boots GmbH. Specifically, the Company publicly announced goals for fiscal year 2016 of $1 billion in combined synergies and $9 to $9.5 billion in adjusted earnings before interest and taxes ("EBIT") for the combined entity, but concealed a earnings shortfall of $1.8 to $2.3 billion for fiscal year 2016 and the reasons for the shortfall from the investing public.
On August 4, 2014, the Company announced that its CFO Wade Miquelon would be resigning. Then, on August 6, 2014, the Company lowered the fiscal year 2016 EBIT target to $7.2 billion, $1.8 billion below the low-end and $2.3 billion below the high-end of the range that they had previously announced to investors. On this news, shares of Walgreens fell sharply, falling from $69.12 per share on August 5, 2014 to close at $59.21 per share on August 6, 2014, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 9, 2015. If you wish to join the litigation, go to the firm's website at http://www.rosenlegal.com/cases-573.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
CONTACT: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 email@example.com firstname.lastname@example.org email@example.com www.rosenlegal.comNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...